Expression of Inflammatory Genes in Murine Lungs in a Model of Experimental Pulmonary Hypertension: Effects of an Antibody-Based Targeted Delivery of Interleukin-9.

drug delivery gene expression analysis inflammation pulmonary hypertension

Journal

Advances in respiratory medicine
ISSN: 2543-6031
Titre abrégé: Adv Respir Med
Pays: Switzerland
ID NLM: 101697329

Informations de publication

Date de publication:
03 Jan 2024
Historique:
received: 11 11 2023
revised: 19 12 2023
accepted: 27 12 2023
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 22 1 2024
Statut: epublish

Résumé

Pathogenesis of pulmonary hypertension (PH) is a multifactorial process driven by inflammation and pulmonary vascular remodeling. To target these two aspects of PH, we recently tested a novel treatment: Interleukin-9 (IL9) fused to F8, an antibody that binds to the extra-domain A of fibronectin (EDA To evaluate possible F8IL9 effects on PH-associated inflammatory processes, we analysed the expression of genes involved in pulmonary immune responses. We applied the monocrotaline (MCT) model of PH in mice ( Compared with the controls, 19 genes exhibited relevant (+2.5-fold) upregulation in the PH group without treatment. Gene expression levels in F8IL9-treated lung tissue were reduced compared to the PH group without treatment. This was the case especially for CCL20, CXCL5, C-reactive protein, pentraxin related (CRP In accordance with the hypothesis stated above, F8IL9 treatment diminished the upregulation of some genes associated with inflammation in a PH animal model. Therefore, we hypothesize that IL9-based immunocytokine treatment will likely modulate various inflammatory pathways.

Sections du résumé

BACKGROUND BACKGROUND
Pathogenesis of pulmonary hypertension (PH) is a multifactorial process driven by inflammation and pulmonary vascular remodeling. To target these two aspects of PH, we recently tested a novel treatment: Interleukin-9 (IL9) fused to F8, an antibody that binds to the extra-domain A of fibronectin (EDA
PURPOSE OBJECTIVE
To evaluate possible F8IL9 effects on PH-associated inflammatory processes, we analysed the expression of genes involved in pulmonary immune responses.
METHODS METHODS
We applied the monocrotaline (MCT) model of PH in mice (
RESULTS RESULTS
Compared with the controls, 19 genes exhibited relevant (+2.5-fold) upregulation in the PH group without treatment. Gene expression levels in F8IL9-treated lung tissue were reduced compared to the PH group without treatment. This was the case especially for CCL20, CXCL5, C-reactive protein, pentraxin related (CRP
CONCLUSION CONCLUSIONS
In accordance with the hypothesis stated above, F8IL9 treatment diminished the upregulation of some genes associated with inflammation in a PH animal model. Therefore, we hypothesize that IL9-based immunocytokine treatment will likely modulate various inflammatory pathways.

Identifiants

pubmed: 38247549
pii: arm92010005
doi: 10.3390/arm92010005
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

27-35

Auteurs

Judith Heiss (J)

Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
Else Kröner Graduate School for Medical Students "JSAM", Jena University Hospital, 07747 Jena, Germany.

Katja Grün (K)

Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.

Isabell Singerer (I)

Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.

Laura Tempel (L)

Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.

Mattia Matasci (M)

Philochem AG, 8112 Otelfingen, Switzerland.

Christian Jung (C)

Medical Faculty, Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine University Düsseldorf, 40225 Düsseldorf, Germany.

Alexander Pfeil (A)

Department of Internal Medicine III, University Hospital Jena, 07747 Jena, Germany.

P Christian Schulze (PC)

Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.

Dario Neri (D)

Philochem AG, 8112 Otelfingen, Switzerland.

Marcus Franz (M)

Department of Internal Medicine I, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.

Classifications MeSH